AstraZeneca
According to a recent Guardian article, a long-term global study revealed that a daily pill called osimertinib can reduce the risk of dying from lung cancer by 51%. The study, led by Yale University and presented at the American Society of Clinical Oncology's annual meeting, involved patients with non-small cell lung cancer who had a mutation of the EGFR gene, which is present in about a quarter of global lung cancer cases. The results showed that taking osimertinib after surgery significantly lowered the risk of death and also halved the risk of disease recurrence.
